Minutia

Minutia is a next-generation cell therapy company working towards a functional cure for type 1 diabetes through a transplant of insulin-producing cells combined with nanosensors. The company's novel approach combines robust and controlled insulin-producing cell transplants with in vivo monitoring capability using a unique nanoparticle platform, aiming to revolutionize the clinical landscape for diabetes and cell replacement therapy. Founded by CEO Katy Digovich, who has lived with type 1 diabetes for over 30 years, Minutia is supported by non-dilutive funding from the NIH, California Institute for Regenerative Medicine (CIRM), and JDRF, and is backed by SOSV via an IndieBio cohort.